AbbVie (ABBV) EBT Margin (2012 - 2026)
AbbVie (ABBV) reported EBT Margin of 6.93% for Q1 2026, down 552.0% year-over-year from 1.53% in Q1 2025, and down 56.86% on a QoQ basis from 16.05% in Q4 2025.
AbbVie (ABBV) has 15 years of EBT Margin data on file, last reported at 6.93% in Q1 2026.
- Quarterly EBT Margin fell 552.0% year-over-year to 6.93% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9.51% (up 320.0% YoY) and the FY2025 annual result came in at 10.79%, up 419.0% from the prior year.
- EBT Margin retreated to 6.93% in Q1 2026 per ABBV's latest filing, from 16.05% in the prior quarter.
- Across five years, EBT Margin topped out at 36.41% in Q1 2022 and bottomed at 15.02% in Q4 2024.
- The 5-year median for EBT Margin is 14.02% (2023), against an average of 12.8%.
- The widest annual swing landed in 2023, when EBT Margin tumbled 3252 bps; it then jumped 3108 bps in 2025.
- Tracing ABBV's EBT Margin over 5 years: stood at 19.61% in 2022, then plunged by 57 bps to 8.47% in 2023, then slumped by 277 bps to 15.02% in 2024, then soared by 207 bps to 16.05% in 2025, then tumbled by 57 bps to 6.93% in 2026.
- Per Business Quant, the three latest ABBV EBT Margin figures stand at 6.93% (Q1 2026), 16.05% (Q4 2025), and 4.53% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 44.70% |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 24.89% |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 6.93% |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -21.49% |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 24.18% |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 37.07% |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 135.53% |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 28.20% |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.93% |
| Dec 31, 2025 | 16.05% |
| Sep 30, 2025 | 4.53% |
| Jun 30, 2025 | 10.08% |
| Mar 31, 2025 | 12.45% |
| Dec 31, 2024 | -15.02% |
| Sep 30, 2024 | 14.41% |
| Jun 30, 2024 | 14.84% |
| Mar 31, 2024 | 14.26% |
| Dec 31, 2023 | 8.47% |
| Sep 30, 2023 | 14.02% |
| Jun 30, 2023 | 18.82% |
| Mar 31, 2023 | 3.89% |
| Dec 31, 2022 | 19.61% |
| Sep 30, 2022 | 29.71% |
| Jun 30, 2022 | 8.11% |
| Mar 31, 2022 | 36.41% |
| Dec 31, 2021 | 28.69% |
| Sep 30, 2021 | 25.71% |
| Jun 30, 2021 | 8.33% |
| Mar 31, 2021 | 29.72% |
| Dec 31, 2020 | -10.87% |
| Sep 30, 2020 | 19.38% |
| Jun 30, 2020 | -6.65% |
| Mar 31, 2020 | 35.94% |
| Dec 31, 2019 | 35.32% |
| Sep 30, 2019 | 23.60% |
| Jun 30, 2019 | 9.78% |
| Mar 31, 2019 | 32.50% |
| Dec 31, 2018 | -28.57% |
| Sep 30, 2018 | 33.52% |
| Jun 30, 2018 | 24.31% |
| Mar 31, 2018 | 35.25% |
| Dec 31, 2017 | 15.42% |
| Sep 30, 2017 | 29.95% |
| Jun 30, 2017 | 33.89% |
| Mar 31, 2017 | 31.91% |
| Dec 31, 2016 | 29.40% |
| Sep 30, 2016 | 31.31% |
| Jun 30, 2016 | 32.49% |
| Mar 31, 2016 | 29.81% |
| Dec 31, 2015 | 30.06% |
| Sep 30, 2015 | 27.71% |
| Jun 30, 2015 | 1,568.22% |
| Mar 31, 2015 | 27.70% |
| Dec 31, 2014 | -19.02% |
| Sep 30, 2014 | 13.69% |
| Jun 30, 2014 | 29.09% |
| Mar 31, 2014 | 28.18% |
| Dec 31, 2013 | 28.15% |
| Sep 30, 2013 | 27.61% |
| Jun 30, 2013 | 29.16% |
| Mar 31, 2013 | 28.62% |
| Dec 31, 2012 | 32.90% |
| Sep 30, 2012 | 35.58% |
| Jun 30, 2012 | 31.20% |
| Mar 31, 2012 | 24.11% |